Bristol submits hepatitis C drugs for FDA review

04/8/2014 | FDAnews

Bristol-Myers Squibb has filed new-drug applications with the FDA for approval to market its experimental drugs daclatasvir and asunaprevir as a treatment for hepatitis C genotype 1b. The combination regimen previously received breakthrough therapy status from the FDA.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL